--- title: "U.S. stock night trading opens with fluctuations: POET Tech rises 10.53% in night trading; Network 1 Tech falls 8.84% in night trading" type: "News" locale: "en" url: "https://longbridge.com/en/news/284128975.md" description: "POET Tech rose 10.53% in after-hours trading; Network 1 Tech fell 8.84% in after-hours trading; Intellia Therapeutics rose 27.73% in after-hours trading; Organon rose 21.05% in after-hours trading; Brown-Forman rose 14.50% in after-hours trading" datetime: "2026-04-27T00:17:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284128975.md) - [en](https://longbridge.com/en/news/284128975.md) - [zh-HK](https://longbridge.com/zh-HK/news/284128975.md) --- # U.S. stock night trading opens with fluctuations: POET Tech rises 10.53% in night trading; Network 1 Tech falls 8.84% in night trading **U.S. Stock Night Market Opening Movements** POET Tech rose 10.53% in the night market. Based on recent key news: 1. On April 25, POET Tech's stock price rose 31.14% on Friday, continuing a year-to-date increase of 141.23%. Previously, Wolfpack Research released a short report, but the company's CEO Mika refuted the report and announced a purchase order from Marvell. This news boosted market confidence and drove the stock price up. 2. On April 24, POET Tech's stock price traded above its 20-day simple moving average by 77.3% and its 100-day simple moving average by 86.5%. The relative strength index (RSI) was 83.44, indicating strong upward pressure. Over the past 12 months, the stock price has increased by 209.31%, indicating a sustained upward trend. 3. On April 24, POET Tech's stock price approached its 52-week high of $12.95, showing continued upward momentum. The company is expected to release its next financial update on May 13, with an anticipated earnings per share loss of 5 cents and revenue expected to be $347.97K. Industry trends show strong upward pressure, and caution is advised regarding excessive volatility risks. Network 1 Tech fell 8.84% in the night market. Based on recent key news: 1. On April 24, Network 1 Technologies Inc. announced that the company does not undertake any obligation to update or revise any forward-looking statements. This statement may raise market concerns about the company's future development, leading to a decline in stock price. 2. On April 24, the company released original content through ACCESS Newswire, further clarifying the details of the above statement. This information heightened investor concerns, causing the stock price to continue to decline. 3. There have been no other significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. **Top Gaining Stocks in the U.S. Night Market** Intellia Therapeutics rose 27.73% in the night market. Based on recent key news: 1. On April 24, Intellia announced that it will release the topline results of the global Phase 3 HAELO trial on April 27. This is the first Phase 3 result for an in vivo CRISPR gene editing candidate, which could become a milestone for its platform's clinical validation, driving the stock price up. 2. On April 24, Intellia's stock price rose 19.27% in after-hours trading, reflecting positive market expectations for the upcoming clinical data release. 3. On April 25, Intellia collaborated with strategic partners to expand the impact of its genome editing methods, further enhancing investor confidence. The gene editing industry has performed strongly recently, with significant capital inflows Organon rose 21.05% in after-hours trading. Based on recent key news: 4. On April 25, Sun Pharmaceutical submitted multiple bids to acquire Organon, with the latest bid at $13 billion, setting a record for the company's largest acquisition. This news drove Organon's stock price up 25.47%, with a significant increase in trading volume. 5. On April 26, Sun Pharmaceutical and Organon signed a final agreement for a cash acquisition of Organon for $11.75 billion. This transaction has been approved by the boards of both companies and is expected to be completed in early 2027, pending regulatory approval and shareholder votes. 6. On April 27, Sun Pharmaceutical announced the acquisition of all outstanding shares of Organon at a price of $14 per share, further confirming the acquisition details and driving the stock price up. Industry consolidation is accelerating, trading is active, and capital inflow is evident. Brown-Forman rose 14.50% in after-hours trading, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation ### Related Stocks - [POET.US](https://longbridge.com/en/quote/POET.US.md) - [NTIP.US](https://longbridge.com/en/quote/NTIP.US.md) ## Related News & Research - [Poet Technologies sank today -- is the stock a buy right now?](https://longbridge.com/en/news/286625118.md) - [Why Poet Technologies stock skyrocketed this week](https://longbridge.com/en/news/286681063.md) - [POET Technologies GAAP EPS of -$0.08 misses by $0.03, revenue of $0.5M beats by $0.25M](https://longbridge.com/en/news/286510324.md) - [POET Stock Jumped on $500 Million Deal With Lumilens. Its Financials Have a Long Way to Go.](https://longbridge.com/en/news/286600014.md) - [POET Technologies Posts Higher Q1 2026 Revenue but Swings to Net Loss as Costs Surge](https://longbridge.com/en/news/286588263.md)